- Blog
- Presencia de GEICAM en San Antonio Breast Cancer Symposium SABCS 2023
Presencia de GEICAM en San Antonio Breast Cancer Symposium SABCS 2023
lunes 4 diciembre 2023GEICAM presentará en el próximo San Antonio Breast Cancer Symposium (SABCS23) que se celebrará en Texas (EEUU) del 5 al 9 de diciembre, las siguientes comunicaciones (póster) de estudios del Grupo:
- STEEP criteria v2.0 validation: A multi-trial analysis using GEICAM and TRIO adjuvant trials to evaluate surrogate endpoints for overall survival.
- Body Mass Index and Treatment Efficacy in advanced Luminal Breast Cancer: Insights from the (GEICAM/2013-02) PEARL trial.
- Lower pre-treatment b-cell gene expression signatures correspond with improved overall survival with palbociclib + endocrine therapy in HR+/HER2- metastatic breast cancer: a biomarker analysis from the (GEICAM/2013- 02) PEARL trial.
- BRCA mutated Male Breast Cancer, hallmarks of a distinct disease. Data from the Spanish Male Breast Cancer Registry (GEICAM/2016-04).
- Real-world features and outcomes of young, advanced breast cancer (ABC) patients (pts) from the (GEICAM/2014-03) RegistEM study.
- Deciphering pregnancy-associated breast cancer: distinctive molecular profile and clinical implications from the (GEICAM/2017- 07) EMBARCAM study.
- Randomized Phase II trial evaluating three anti-diarrhoeal prophylaxis strategies in patients with HER2+ / HR+ early breast cancer treated with extended adjuvant neratinib: (GEICAM/2018-06) DIANER study.
Adicionalmente, se presentarán cinco comunicaciones orales de estudios en los que GEICAM participa en el listado de autores:
- Adding atezolizumab to adjuvant chemotherapy for stage II and III triple negative breast cancer is unlikely to improve efficacy: interim analysis of the ALEXANDRA/IMpassion030 phase 3 trial.
- Fertility preservation and assisted reproductive technologies (ART) in breast cancer (BC) patients (pts) interrupting endocrine therapy (ET) to attempt pregnancy.
- Ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2- early breast cancer: final invasive disease– free survival (iDFS) analysis from the NATALEE trial.
- Protocol-defined biomarker analysis in the PALLAS adjuvant trial: genomic subtype derived from RNA sequencing of HR+/HER2- eBC.
- Pathologic complete response (pCR) of neoadjuvant therapy with or without atezolizumab in HER2- positive, early high-risk and locally advanced breast cancer: APTneo Michelangelo randomized trial.
Y un póster discusión:
- Clinical and Genomic Features of ER-Positive/HER2-negative Metastatic Breast Cancer in AURORA Molecular Screening Initiative (BIG 14-01): Mechanisms of Endocrine Therapy Resistance and Implications for Adjuvant Approaches.
Por último, se presentarán cuatro pósteres de estudios en los que GEICAM participa en el listado de autores y dos pósteres de estudios en los que participa GEICAM (sin autoría).
Pueden consultar más información y horarios de estas comunicaciones en este enlace.